论文部分内容阅读
Rucaparib由辉瑞制药公司研发,2015年4月被美国食品药品监督管理局(FDA)授予治疗卵巢癌突破性疗法资格,美国Clovis肿瘤公司于2011年从辉瑞制药公司获得授权,负责在美国申请上市并取得生产和销售经营权。美国FDA于2016年12月19日加速审批上市,商品名为Rubraca。该文对芦卡帕尼的非临床毒理学和临床药理学、临床试验、适应证、剂量与用法、用药注意事项、不良反应及知识产权状态和国内外研究进展等进行介绍。
Developed by Pfizer, Rucaparib was awarded the FDA’s breakthrough in breakthrough therapies for ovarian cancer in April 2015. Clovis Oncology America was licensed by Pfizer Pharmaceuticals in 2011 to apply for listing in the United States Obtain production and sales management rights. The U.S. FDA accelerated its approval process on December 19, 2016 under the trade name Rubraca. This article introduces the non-clinical toxicology and clinical pharmacology, clinical trials, indications, dosage and usage, medication considerations, adverse reactions and intellectual property status of ascorbani and the research progress at home and abroad.